Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Intranasal BBV154 vs COVAXIN for COVID-19 Immunogenicity and Safety
NCT05522335Phase 3Unknown
- Sponsor
- Bharat Biotech
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of iNCOVACC in coronavirus disease 2019 (COVID-19), sponsored by Bharat Biotech. Status: unknown.
02
Drugs
iNCOVACC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05522335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522335.